Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

Stroke, Ischemic Clinical Trial

Official title:

Feasibility of Trigeminal and Vagus Nerve Stimulation in Subjects With Chronic Upper Extremity Deficits After Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06288217
• Other study ID #: NS-CIP-001
• Status: Recruiting
• Phase: N/A
• Start date: March 5, 2024
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: NeuraStasis, Inc
• Contact: Kirt Gill, MD
• Phone: (832) 925-3302
• Email: clinical[@]neurastasis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, pilot study of up to 25 subjects with residual upper extremity deficits at least six months after an ischemic stroke. The purpose of the study is to evaluate the initial clinical safety, device functionality, and treatment effect of non-invasive electrical stimulation of the trigeminal and/or vagus nerves (nTVNS) using the NeuraStasis Stimulator System adjunctive to rehabilitation. Subjects will either receive the intervention or control-sham stimulation. The study will inform the design and implementation of a pivotal study.

Description:

This pilot study will proceed in two phases: Phase I, an unblinded blinded stage and Phase II, a blinded stage comparing intervention and sham groups.

Phase I will consist of 5 subjects, unblinded, receiving nTVNS. This phase will test the usability of the device and de-risk the use of nTVNS during rehabilitation. Visits will include consent and baseline evaluation followed by 6 weeks of treatment consisting of the standard of care with nTVNS. Rehabilitation and treatment will occur at a cadence of 3 sessions per week. Primary endpoints will be collected after 6 weeks.

Phase II will consist of a Prospective Randomized Open, Blinded Endpoint (PROBE) design. Subjects will be randomized to an intervention nTVNS group or a control sham stimulation group. The control sham stimulation consists of standard-of-care rehabilitation with only a minimal amount of nTVNS delivered at the start of each session during a tolerability assessment intended to support further blinding for therapists and subjects. The same evaluations, sessions, and endpoints will occur as those in Phase I.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• History of unilateral supratentorial ischemic stroke that occurred at least 6 months but not more than 10 years prior to enrollment.

• Age >40 years and <80 years.

• Fugl-Meyer Assessment, Upper Limb (FMA-UE) baseline score of 20 to 50 (inclusive of 20 and 50).

• Ability to communicate, understand, and provide appropriate consent. Subjects should be able to follow two-step commands.

• Right- or left-sided weakness of the upper extremity.

Exclusion Criteria

• Participant has implanted metallic or electronic devices in the head or neck

• Hemorrhagic stroke or a heterogenous lesion etiology

• Participant has a cardiac pacemaker or implanted or wearable defibrillator

• Participant skin in the stimulation area has open wounds, skin eruptions, swollen, infected, or inflamed areas, or skin abnormalities that could be cancerous

• Advanced cardiac, pulmonary, liver, kidney dysfunction or blood system disease

• Participant has a fever or shows clinical signs concerning for an infectious disease

• Other neurologic or musculoskeletal diseases that could interfere with the assessments of this study

• Low heart rate (<60 bpm) from a cardiac conduction block or related etiology

• Participant has a history of trigeminal neuralgia

• Participant has a history of Bell's Palsy

• History of cranial nerve neuropathy (including facial nerve injury), carotid surgery, vagotomy, or other surgical intervention on the vagus nerve

• History of recurrent syncopal events

• Known or newly-discovered aneurysm or arteriovenous malformation

• Patients who have any terminal illness such that the patient would not be expected to survive more than 90 days

• Botox injections 12 weeks prior to or during therapy

Related Conditions & MeSH terms

• Ischemic Stroke
• Paresis
• Stroke
• Stroke, Ischemic
• Upper Extremity Paresis

Intervention

Device:
• NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)
Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements

Other:
• Upper Limb Rehabilitation
Rehabilitation movements to improve upper limb function after stroke
• Sham Stimulation
Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center at Houston	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
NeuraStasis, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fugl-Meyer Assessment, Upper Limb (FMA-UE) Average Change	The Fugl-Meyer Assessment, Upper Limb (FMA-UE) will be analyzed for the difference in average change after 6 weeks of therapy compared to baseline. The FMA-UE is a common scale used to measure motor impairment after a stroke. The range is 0 (more impairment) to 66 (no impairment).	Within 7 days of completing 6 weeks of rehabilitation
Secondary	Action Research Arm Test (ARAT) Average Change	The ARAT will be analyzed for the difference in average change after 6 weeks of therapy compared to baseline. The ARAT is a widely used clinical scoring tool for stroke rehabilitation. The test consists of 19 items that are grouped into four sub-tests: grasp, grip, pinch, and gross movement. The total score on the ARAT ranges from 0 to 57, with a higher score indicating better performance.	Within 7 days of completing 6 weeks of rehabilitation
Secondary	Fugl-Meyer Assessment, Upper Limb (FMA-UE) Response %	The FMA-UE will be analyzed for the % of subjects that responded to treatment defined as achieving an effect equivalent to a greater than the minimal clinically important difference.	Within 7 days of completing 6 weeks of rehabilitation
Secondary	Proportion of subjects completing all pre-specified treatment doses	Proportion of subjects completing all pre-specified treatment sessions across the 6 weeks of rehabilitation	Upon completion of 6 weeks of rehabilitation
Secondary	Subject Questionnaire on Device Usage	A questionnaire that evaluates subjects' level of comfort during use of the device on a 5-point scale, with 5 being the most comfortable and 1 being the least comfortable.	Upon completion of 6 weeks of rehabilitation
Secondary	Therapist Questionnaire on Device Usage	A questionnaire that evaluates the ease of use of the device by therapists during the administration of rehab with the device on a 5-point scale, with 5 being the most usable and 1 being the least usable.	Upon completion of 6 weeks of rehabilitation
Secondary	Serious adverse device effects (SADE) rate at 24 hours post-therapy session	SADE rate at 24 hours post-therapy sessions	Up to 24 hours after each therapy session and ending 24 hours post-last therapy session at 6 weeks of rehabilitation
Secondary	Stroke impact scale (SIS) Summative Score Average Change	The Stroke Impact Scale (SIS) is a multidimensional self-reported measure of health-related quality of life. The SIS includes 59 items and assesses 8 domains: strength (four items), memory and thinking (seven items), emotion (nine items), communication (seven items), activities of daily living (ten items), mobility (nine items), hand function (five items) and participation and function in life activities (ten items). Each item is rated using a 5-point Likert-type scale (1 = an inability to complete the item; 5 = no difficulty experienced at all) and a global score is calculated as a summative score of each domain, transformed into a 0-100 scale. It includes an extra question on the person´s perceived stroke recovery measured in the form of a visual analogue scale from 0-100. The summative score will be analyzed for the difference in average change after 6 weeks of therapy compared to baseline.	Within 7 days of completing 6 weeks of rehabilitation
Secondary	Analysis of the number of stimulations per therapy session	The number of paired stimulations initiated each rehabilitation session will be analyzed to understand personalized effectiveness and responder likelihood.	Upon completion of 6 weeks of rehabilitation